Want to see DWTX full AI Analyst Report?
Top Page
Dogwood Therapeutics
(NASDAQ:DWTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$2.50
▼(-6.02% Downside)
Action:Reiterated
Date:08/26/26
The score is primarily held back by weak financial performance (no revenue, widening losses, and sustained cash burn), despite a low-debt balance sheet. Technicals are a near-term positive with strong momentum, but overbought indicators temper that strength. Valuation is difficult to support due to negative earnings, and the approved increase in authorized shares adds potential dilution risk.
Positive Factors
Very low leverage
Minimal debt limits interest and refinancing pressure, giving Dogwood greater financial flexibility than a highly leveraged biotech. This provides a relatively stable capital structure while the company funds development, although it does not offset ongoing cash burn.
Negative Factors
No revenue and widening losses
The absence of demonstrated revenue and materially widening losses show that Dogwood has not yet established commercial traction. Persistent operating deficits increase execution risk and require successful development, regulatory progress, or partnering to create future value.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt limits interest and refinancing pressure, giving Dogwood greater financial flexibility than a highly leveraged biotech. This provides a relatively stable capital structure while the company funds development, although it does not offset ongoing cash burn.
Read all positive factors
Dogwood Therapeutics (DWTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$80.22M
Dividend YieldN/A
Average Volume (3M)63.44K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue GrowthN/A
EPS Growth52.36%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.95
Shares Outstanding33,992,554
10 Day Avg. Volume99,151
30 Day Avg. Volume63,444
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.50Price Target Upside407.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Dogwood Therapeutics Business Overview & Revenue Model
Company Description
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading thera...
How the Company Makes Money
null...
Dogwood Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -16.69K | 0.00 | -12.18K | 0.00 | 0.00 | 0.00 |
| EBITDA | -29.30M | -34.03M | -12.25M | -5.30M | -12.25M | -15.96M |
| Net Income | -36.04M | -34.26M | -12.35M | -5.30M | -12.25M | -15.96M |
Balance Sheet | ||||||
| Total Assets | 80.50M | 90.17M | 94.31M | 4.17M | 8.37M | 15.78M |
| Cash, Cash Equivalents and Short-Term Investments | 9.61M | 6.52M | 14.85M | 3.32M | 7.03M | 14.01M |
| Total Debt | 127.21K | 162.60K | 15.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.13M | 15.27M | 30.03M | 358.55K | 1.04M | 1.28M |
| Stockholders Equity | 68.37M | 74.90M | 64.28M | 3.81M | 7.33M | 14.50M |
Cash Flow | ||||||
| Free Cash Flow | -15.11M | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Operating Cash Flow | -15.11M | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Investing Cash Flow | 0.00 | 0.00 | 3.76M | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 11.32M | 7.28M | 16.70M | 1.16M | 4.49M | -97.60K |
Dogwood Therapeutics Technical Analysis
Neutral
2.66
Price Trends
1.85
Positive
1.72
Positive
2.72
Negative
Market Momentum
0.19
Positive
53.06
Neutral
16.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DWTX, the sentiment is Neutral. The current price of 2.66 is above the 20-day moving average (MA) of 2.31, above the 50-day MA of 1.85, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of 16.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DWTX.
Dogwood Therapeutics Risk Analysis
Dogwood Therapeutics disclosed 67 risk factors in its most recent earnings report. Dogwood Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dogwood Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $80.22M | -0.26 | -47.85% | ― | ― | 52.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $20.67M | -2.46 | -56.96% | ― | -56.64% | 64.88% | |
46 Neutral | $7.38M | -0.40 | -124.74% | ― | ― | 71.66% | |
42 Neutral | $7.50M | -0.24 | -126.23% | ― | 12.79% | 37.93% | |
40 Underperform | $3.66M | -0.12 | -423.84% | ― | -8.47% | 25.61% |
* Healthcare Sector Average
DWTX
Dogwood Therapeutics
2.29
-2.61
-53.27%
MRKR
Marker Therapeutics
1.18
0.28
31.70%
BRTX
BioRestorative Therapies
0.15
-1.45
-90.75%
BOLT
Bolt Biotherapeutics
3.90
-1.29
-24.86%
ACXP
Acurx Pharmaceuticals
1.42
-2.66
-65.20%
Dogwood Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Dogwood Therapeutics Shareholders Approve Key Governance Measures
Positive
Jun 17, 2026
On June 16, 2026, Dogwood Therapeutics, Inc. held its annual meeting of stockholders, where 95.17% of the company’s common stock voting power was represented, constituting a quorum and underscoring strong shareholder engagement. Stockholders...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.